Diplomat, RainTree Oncology Services announce agreement
SAN DIEGO — Diplomat Specialty Pharmacy has signed an agreement with a provider of acquisition and management services for oral cancer drugs that the companies said would allow for better access to the drugs and related programs.
RainTree Oncology Services announced the agreement with Flint, Mich.-based Diplomat, saying it was building a network of community oncologists through which members will obtain drugs at contracted prices and that the agreement would improve access to clinical and medication management programs.
"We are honored to be chosen by RainTree to be their specialty pharmacy partner," Diplomat president and CEO Phil Hagerman said. "Working in close partnership with RainTree will facilitate enhanced services to RainTree physicians and improved outcomes for their patients. This model will secure access to complex oral oncolytics as well as implement drug-specific algorithms that will help mimic clinical trial efficacy."
Changes in healthcare economics have affected how community oncology practices operate, RainTree said, putting pressure on their ability to deliver services to patients. This, according to the company, can make acquisition and management of oral cancer drugs problematic because the drugs are expensive and often not fully reimbursed.
FDA approves Antares Pharma’s overactive bladder drug
PARSIPPANY, N.J. — The Food and Drug Administration has approved a topical gel made by Antares Pharma for overactive bladder.
Watson Pharmaceuticals announced Thursday the approval of oxybutynin gel in the 3% strength, which it will launch next year under a licensing agreement with Antares.
"This significant achievement represents Antares’ first [new drug application] approval and is the culmination of a development program managed successfully by our clinical and regulatory team, Antares president and CEO Paul Wotton said. "Watson Pharmaceuticals proven track record of commercializing transdermal products to urologists and other significant prescribers of [overactive bladder] treatments makes them an ideal partner to execute a successful product launch."
PCPAN reacts to Express Scripts Senate testimony
WASHINGTON — Preserve Community Pharmacy Access Now — a coalition of consumers, businesses and community-based pharmacists banded together for the purpose of opposing the planned merger between Express Scripts and Medco Health Solutions — on Thursday responded to testimony provided by George Paz, Express Scripts CEO, before the Senate Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights hearing held Tuesday.
According to PCPAN, Paz testified before the Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights and responded to a question about the merger with, "I can’t stop certain pharmacies from going out of business," less than 24 hours after releasing a study claiming that the merger of Express Scripts and Medco would save consumers billions of dollars in healthcare costs.
"Express Scripts CEO George Paz testified that, ‘patients-not-profits must come first,’ but the remainder of his testimony clearly demonstrated that this proposed merger would result in the elimination of jobs and limit access to pharmacies for some of the most vulnerable citizens in underserved communities throughout the country," stated former Rep. Eva Clayton, chairman of the Preserve Community Pharmacy Access Now coalition. "Particularly now, with an unemployment rate of nearly 9% and no relief in sight, America can ill afford the loss of more jobs and access to pharmacy care that would result from the merger of these two behemoth middlemen."